Nivolumab plus relatlimab vs nivolumab alone for the adjuvant treatment of completely resected stage III–IV melanoma: Primary results from RELATIVITY-098.
Georgina V. Long(The University of Sydney), Hussein A. Tawbi(The University of Texas MD Anderson Cancer Center), Margaret K. Callahan(Cornell University), Alicia Cheong(Bristol-Myers Squibb (United Kingdom)), Ahmad A. Tarhini(UPMC Hillman Cancer Center), Ioannis Thomas(Sensap (Greece)), Paolo A. Ascierto(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Andréia Cristina de Melo(National Cancer Institute), Dirk Schadendorf(National Center for Tumor Diseases), Sunandana Chandra(Northwestern University), Peter Koelblinger(Paracelsus Medical University), Eva Muñoz‐Couselo(Vall d'Hebron Hospital Universitari), Jun Guo(Soochow University), G. Quéreux(Nantes Université), Helen Gogas(National and Kapodistrian University of Athens), Patrick Djidel(Bristol-Myers Squibb (United States)), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Reinhard Dummer(University of Zurich), Sonia Dolfi(Bristol-Myers Squibb (United States))
Cited by 7
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Pembrolizumab versus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2015|5.9k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Nivolumab plus Ipilimumab in Advanced Melanoma
|New England Journal of Medicine|2013|4.2k
Melanoma exosomes educate bone marrow progenitor cells toward a pro-metastatic phenotype through MET
|Nature Medicine|2012|3.7k